Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis

The Kyushu University Liver Disease Study (KULDS) Group

研究成果: ジャーナルへの寄稿記事

26 引用 (Scopus)

抄録

Older patients with chronic hepatitis C virus (HCV) infection have historically been designated difficult-to-treat. We evaluated the efficacy and safety of sofosbuvir (nucleotide NS5B polymerase inhibitor) plus ribavirin for patients with HCV genotype 2 infection in a real-world clinical setting, with the focus on elderly patients aged ≥ 65. This large, multicenter study consisted of 446 Japanese HCV genotype 2 patients (303 treatment-naïve and 143 treatment-experienced), including 190 (42.6%) aged ≥ 65 and 90 (20.2%) with compensated cirrhosis. Efficacy was assessed by the sustained virological response 12 weeks post-treatment (SVR12). The overall SVR12 rate was 95.7% (427/446), and the SVR12 rate of patients aged ≥ 65 was 95.3% (181/190). For treatment-naïve patients, almost all with compensated cirrhosis (95.6%, 43/45) achieved SVR12, irrespective of age. For treatment-experienced patients, cirrhosis undermined the treatment outcome, both for the aged ≥65 (SVR12: 80.0%, 20/25) and <65 (85.0%, 17/20) patient groups when compared to non-cirrhosis patients (≥65: 95.7%, 45/47 and < 65: 96.2%, 50/52). The most common adverse effect was anemia (hemoglobin <10 g/dL), especially for patients aged ≥ 65 with the inosine triphosphate pyrophosphatase CC genotype at rs1127354 (26.2%, 33/126). Notably, ribavirin reduction was not related to treatment failure. Only three (0.7%) patients, all aged ≥ 65, discontinued treatment, but all achieved SVR12. Sofosbuvir plus ribavirin for HCV genotype 2 was effective for patients aged ≥65, especially those who were treatment-naïve or treatment-experienced/non-cirrhosis.

元の言語英語
ページ(範囲)37-44
ページ数8
ジャーナルAntiviral Research
136
DOI
出版物ステータス出版済み - 12 1 2016

Fingerprint

Ribavirin
Hepacivirus
Fibrosis
Genotype
Safety
Therapeutics
Sofosbuvir
Pyrophosphatases
Inosine Triphosphate
Chronic Hepatitis C
Virus Diseases
Treatment Failure
Multicenter Studies
Anemia
Hemoglobins
Nucleotides

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Virology

これを引用

Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. / The Kyushu University Liver Disease Study (KULDS) Group.

:: Antiviral Research, 巻 136, 01.12.2016, p. 37-44.

研究成果: ジャーナルへの寄稿記事

The Kyushu University Liver Disease Study (KULDS) Group. / Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. :: Antiviral Research. 2016 ; 巻 136. pp. 37-44.
@article{9a4aeb953fb94f0097573a7d38b42d70,
title = "Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis",
abstract = "Older patients with chronic hepatitis C virus (HCV) infection have historically been designated difficult-to-treat. We evaluated the efficacy and safety of sofosbuvir (nucleotide NS5B polymerase inhibitor) plus ribavirin for patients with HCV genotype 2 infection in a real-world clinical setting, with the focus on elderly patients aged ≥ 65. This large, multicenter study consisted of 446 Japanese HCV genotype 2 patients (303 treatment-na{\"i}ve and 143 treatment-experienced), including 190 (42.6{\%}) aged ≥ 65 and 90 (20.2{\%}) with compensated cirrhosis. Efficacy was assessed by the sustained virological response 12 weeks post-treatment (SVR12). The overall SVR12 rate was 95.7{\%} (427/446), and the SVR12 rate of patients aged ≥ 65 was 95.3{\%} (181/190). For treatment-na{\"i}ve patients, almost all with compensated cirrhosis (95.6{\%}, 43/45) achieved SVR12, irrespective of age. For treatment-experienced patients, cirrhosis undermined the treatment outcome, both for the aged ≥65 (SVR12: 80.0{\%}, 20/25) and <65 (85.0{\%}, 17/20) patient groups when compared to non-cirrhosis patients (≥65: 95.7{\%}, 45/47 and < 65: 96.2{\%}, 50/52). The most common adverse effect was anemia (hemoglobin <10 g/dL), especially for patients aged ≥ 65 with the inosine triphosphate pyrophosphatase CC genotype at rs1127354 (26.2{\%}, 33/126). Notably, ribavirin reduction was not related to treatment failure. Only three (0.7{\%}) patients, all aged ≥ 65, discontinued treatment, but all achieved SVR12. Sofosbuvir plus ribavirin for HCV genotype 2 was effective for patients aged ≥65, especially those who were treatment-na{\"i}ve or treatment-experienced/non-cirrhosis.",
author = "{The Kyushu University Liver Disease Study (KULDS) Group} and Eiichi Ogawa and Norihiro Furusyo and Hideyuki Nomura and Kazuhiro Takahashi and Nobuhiko Higashi and Akira Kawano and Kazufumi Dohmen and Takeaki Satoh and Koichi Azuma and Makoto Nakamuta and Toshimasa Koyanagi and Masaki Kato and Shinji Shimoda and Eiji Kajiwara and Jun Hayashi",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.antiviral.2016.10.012",
language = "English",
volume = "136",
pages = "37--44",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis

AU - The Kyushu University Liver Disease Study (KULDS) Group

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

AU - Nomura, Hideyuki

AU - Takahashi, Kazuhiro

AU - Higashi, Nobuhiko

AU - Kawano, Akira

AU - Dohmen, Kazufumi

AU - Satoh, Takeaki

AU - Azuma, Koichi

AU - Nakamuta, Makoto

AU - Koyanagi, Toshimasa

AU - Kato, Masaki

AU - Shimoda, Shinji

AU - Kajiwara, Eiji

AU - Hayashi, Jun

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Older patients with chronic hepatitis C virus (HCV) infection have historically been designated difficult-to-treat. We evaluated the efficacy and safety of sofosbuvir (nucleotide NS5B polymerase inhibitor) plus ribavirin for patients with HCV genotype 2 infection in a real-world clinical setting, with the focus on elderly patients aged ≥ 65. This large, multicenter study consisted of 446 Japanese HCV genotype 2 patients (303 treatment-naïve and 143 treatment-experienced), including 190 (42.6%) aged ≥ 65 and 90 (20.2%) with compensated cirrhosis. Efficacy was assessed by the sustained virological response 12 weeks post-treatment (SVR12). The overall SVR12 rate was 95.7% (427/446), and the SVR12 rate of patients aged ≥ 65 was 95.3% (181/190). For treatment-naïve patients, almost all with compensated cirrhosis (95.6%, 43/45) achieved SVR12, irrespective of age. For treatment-experienced patients, cirrhosis undermined the treatment outcome, both for the aged ≥65 (SVR12: 80.0%, 20/25) and <65 (85.0%, 17/20) patient groups when compared to non-cirrhosis patients (≥65: 95.7%, 45/47 and < 65: 96.2%, 50/52). The most common adverse effect was anemia (hemoglobin <10 g/dL), especially for patients aged ≥ 65 with the inosine triphosphate pyrophosphatase CC genotype at rs1127354 (26.2%, 33/126). Notably, ribavirin reduction was not related to treatment failure. Only three (0.7%) patients, all aged ≥ 65, discontinued treatment, but all achieved SVR12. Sofosbuvir plus ribavirin for HCV genotype 2 was effective for patients aged ≥65, especially those who were treatment-naïve or treatment-experienced/non-cirrhosis.

AB - Older patients with chronic hepatitis C virus (HCV) infection have historically been designated difficult-to-treat. We evaluated the efficacy and safety of sofosbuvir (nucleotide NS5B polymerase inhibitor) plus ribavirin for patients with HCV genotype 2 infection in a real-world clinical setting, with the focus on elderly patients aged ≥ 65. This large, multicenter study consisted of 446 Japanese HCV genotype 2 patients (303 treatment-naïve and 143 treatment-experienced), including 190 (42.6%) aged ≥ 65 and 90 (20.2%) with compensated cirrhosis. Efficacy was assessed by the sustained virological response 12 weeks post-treatment (SVR12). The overall SVR12 rate was 95.7% (427/446), and the SVR12 rate of patients aged ≥ 65 was 95.3% (181/190). For treatment-naïve patients, almost all with compensated cirrhosis (95.6%, 43/45) achieved SVR12, irrespective of age. For treatment-experienced patients, cirrhosis undermined the treatment outcome, both for the aged ≥65 (SVR12: 80.0%, 20/25) and <65 (85.0%, 17/20) patient groups when compared to non-cirrhosis patients (≥65: 95.7%, 45/47 and < 65: 96.2%, 50/52). The most common adverse effect was anemia (hemoglobin <10 g/dL), especially for patients aged ≥ 65 with the inosine triphosphate pyrophosphatase CC genotype at rs1127354 (26.2%, 33/126). Notably, ribavirin reduction was not related to treatment failure. Only three (0.7%) patients, all aged ≥ 65, discontinued treatment, but all achieved SVR12. Sofosbuvir plus ribavirin for HCV genotype 2 was effective for patients aged ≥65, especially those who were treatment-naïve or treatment-experienced/non-cirrhosis.

UR - http://www.scopus.com/inward/record.url?scp=84994201177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994201177&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2016.10.012

DO - 10.1016/j.antiviral.2016.10.012

M3 - Article

VL - 136

SP - 37

EP - 44

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -